Zaurategrast

Zaurategrast is a pharmaceutical drug that was developed for the treatment of inflammatory diseases. It is a type of chemokine receptor antagonist, specifically targeting the CXCR2 receptor.

History

Zaurategrast was developed by GlaxoSmithKline, a British multinational pharmaceutical company. The drug was initially developed to treat chronic obstructive pulmonary disease (COPD), but its use has since been expanded to other inflammatory diseases.

Mechanism of Action

Zaurategrast works by blocking the CXCR2 receptor. This receptor is found on the surface of certain white blood cells, and is involved in the body's inflammatory response. By blocking this receptor, Zaurategrast can reduce inflammation and alleviate symptoms of inflammatory diseases.

Clinical Trials

Zaurategrast has undergone several clinical trials to assess its safety and efficacy. These trials have shown that the drug is generally well-tolerated, with few side effects. However, more research is needed to fully understand the long-term effects of Zaurategrast.

Potential Uses

While Zaurategrast was initially developed for COPD, it has potential uses in other inflammatory diseases. These include rheumatoid arthritis, psoriasis, and inflammatory bowel disease. However, further research is needed to confirm the efficacy of Zaurategrast in these conditions.

See Also

• Chemokine receptor antagonist
• GlaxoSmithKline
• Inflammatory diseases

References

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!